Harmony Biosciences Holdings, Inc. — Form 10-Q
Filed August 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
CEO Jeffrey M. Dayno, M.D. and Interim CFO Stephen Mollichella certify the Q2 2026 10-Q (ended June 30, 2026) as of August 4, 2026. Both officers attest to accuracy of financial statements, effectiveness of disclosure controls, and absence of material weaknesses or fraud in internal controls. No material changes to internal control over financial reporting are disclosed. This is routine quarterly certification.
Why this rating
Boilerplate SOX certification; standard attestation with no disclosed control deficiencies, fraud, or changes. Routine quarterly filing requirement.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.